Yu Nan, Zhang Yadi, Kang Lei, Gao Ying, Zhang Junqing, Wu Yuan
Department of Endocrinology, First Hospital, Peking University, Beijing, China.
Department of Ophthalmology, First Hospital, Peking University, Beijing, China.
J Ophthalmol. 2018 Dec 23;2018:3529395. doi: 10.1155/2018/3529395. eCollection 2018.
The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves' ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT).
The right eyes of 36 patients (27 females and 9 males) with Graves' ophthalmopathy (GO) and those of 36 age-, gender-, and diopter-level-matched healthy participants were evaluated. The patients' data were obtained within 3 months after the onset of Graves' disease (GD). Thyroid hormone levels and thyroid-stimulating hormone receptor antibody (TRAb) levels were measured, and the degree of exophthalmos was measured in all patients. Activity is measured by the clinical activity score (CAS). A horizontal scan centered on the fovea was performed in all participants. Five points of choroidal thickness were measured at the fovea (SFCT) and at 1500 m nasal (N1500), 3000 m nasal (N3000), 1500 m temporal (T1500), and 3000 m temporal (T3000) to the fovea.
The CT measurements obtained were (mean ± SD) 313.47 ± 100.32 m, 279.22 ± 85.80 m, 214.64 ± 75.52 m, 313.19 ± 80.36 m, and 298.14 ± 82.75 m in patients with GO and were 256.33 ± 50.18 m, 223.14 ± 59.61 m, 176.69 ± 60.66 m, 250.92 ± 52.184 m, and 239.47 ± 60.35 m in the control group at the foveal, N1500, N3000, T1500, and T3000 measurement points, respectively. The CT in GO patients was significantly increased at all the points compared with the control group ( < 0.05). There was no relationship between the CT and CAS, the degree of exophthalmos, triiodothyronine (T3), tetraiodothyronine (T4), thyroid-stimulating hormone (TSH), or TRAb levels in GO.
CT was found to be increased in GO patients and had poor relationship with CAS, exophthalmos, and thyroid function tests.
本研究的目的是使用频域光学相干断层扫描（SD - OCT）观察格雷夫斯眼病患者脉络膜厚度（CT）的变化。
对36例格雷夫斯眼病（GO）患者（27例女性和9例男性）的右眼以及36例年龄、性别和屈光度水平匹配的健康参与者的右眼进行评估。患者的数据在格雷夫斯病（GD）发病后3个月内获取。测量甲状腺激素水平和促甲状腺激素受体抗体（TRAb）水平，并测量所有患者的眼球突出度。通过临床活动评分（CAS）评估活动度。对所有参与者进行以黄斑为中心的水平扫描。在黄斑中心凹（SFCT）以及距黄斑中心凹鼻侧1500μm（N1500）、鼻侧3000μm（N3000）、颞侧1500μm（T1500）和颞侧3000μm（T3000）处测量五个脉络膜厚度点。
GO患者在黄斑中心凹、N1500、N3000、T1500和T3000测量点处获得的CT测量值（均值±标准差）分别为313.47±100.32μm、279.22±85.80μm、214.64±75.52μm、313.19±80.36μm和298.14±82.75μm，对照组在相应测量点处的CT测量值分别为256.33±50.18μm、223.14±59.61μm、176.69±60.66μm、250.92±52.184μm和239.47±60.35μm。与对照组相比，GO患者在所有测量点处的CT均显著增加（P<0.05）。GO患者的CT与CAS、眼球突出度、三碘甲状腺原氨酸（T3）、四碘甲状腺原氨酸（T4）、促甲状腺激素（TSH）或TRAb水平之间均无相关性。
发现GO患者的CT增加，且与CAS、眼球突出度和甲状腺功能检查的相关性较差。
